ALZFORUM | NETWORKING FOR A CURE
WEB1 day ago · AlzForum is a website that covers the latest research and news on Alzheimer's disease and related dementias. Find out about new discoveries, treatments, biomarkers, and more from experts and peers in the field.
All News - ALZFORUM
WEBSep 6, 2024 · ALZFORUM is a leading online platform for Alzheimer's disease news, research, and discussion. Browse the most recent articles on topics such as biomarkers, immunotherapies, genetics, and more.
Donepezil - ALZFORUM
WEBDonepezil is a cholinesterase inhibitor approved for mild to severe Alzheimer's disease and some other dementias. Learn about its mechanism, efficacy, side effects, and clinical trials from ALZFORUM, a leading source of information on Alzheimer's research.
What Is Early Onset Familial Alzheimer Disease (eFAD)?
WEBEarly onset familial Alzheimer disease (eFAD) is a hereditary form of AD that affects young people with symptoms in their thirties, forties, and fifties. Learn about the three genes that cause eFAD, the differences between eFAD and late-onset AD, and the challenges of diagnosis and treatment.
Trontinemab - ALZFORUM
WEBMay 9, 2024 · Trontinemab is an anti-amyloid monoclonal antibody that uses a brain shuttle technology to cross the blood-brain barrier. It is being developed by Roche for Alzheimer's disease and has shown promising results in lowering brain amyloid in Phase 1 trials.
AL002 - ALZFORUM
WEBNov 6, 2023 · AL002 is a monoclonal antibody that activates microglia and reduces amyloid plaques in mouse models of AD. It is in Phase 2 clinical trials by AbbVie and Alector, after showing safety and efficacy in Phase 1 and Phase 1b studies.
Leqembi - ALZFORUM
WEBLeqembi (BAN2401) is a humanized monoclonal antibody that targets soluble Aβ protofibrils, a form of amyloid that may be toxic to neurons. It has shown promise in slowing cognitive decline and reducing brain amyloid in Phase …
Donanemab | ALZFORUM
WEBFeb 14, 2019 · Donanemab is a humanized IgG1 monoclonal antibody that binds to pyroglutamate-modified Aβ, a form of amyloid plaque in the brain. It is administered intravenously or subcutaneously, and has shown to reduce amyloid load in clinical trials, but also causes ARIA-E in some patients.
Memantine—Good for a Year, But Little Disease Modification
WEBJan 16, 2018 · 12 Jan 2006. The drug memantine is a safe and effective therapy that helps patients suffering from moderate to severe Alzheimer disease for up to a year. However, evidence that the drug might slow the underlying pathology is weak. These are the two main conclusions of a 24-week, open-label extension of a 28-week, randomized clinical trial.
Remternetug - ALZFORUM
WEBRemternetug is an investigational immunotherapy that targets pyroglutamated amyloid plaques in the brain. It is being tested in several Phase 1 and Phase 3 trials for people with mild cognitive impairment or early symptomatic AD, as well as in …